Zevra Therapeutics, Inc. (ZVRA)
11.65
-0.22
(-1.85%)
USD |
NASDAQ |
Aug 24, 16:00
11.66
+0.01
(+0.09%)
After-Hours: 20:00
Zevra Therapeutics Net Income (Quarterly) : 8.393M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 8.393M |
| March 31, 2026 | 36.32M |
| December 31, 2025 | 11.83M |
| September 30, 2025 | -0.544M |
| June 30, 2025 | 74.71M |
| March 31, 2025 | -3.099M |
| December 31, 2024 | -35.74M |
| September 30, 2024 | -33.22M |
| June 30, 2024 | -19.92M |
| March 31, 2024 | -16.62M |
| December 31, 2023 | -15.15M |
| September 30, 2023 | -10.37M |
| June 30, 2023 | -2.573M |
| March 31, 2023 | -13.22M |
| December 31, 2022 | 5.75M |
| September 30, 2022 | -6.616M |
| June 30, 2022 | -24.04M |
| March 31, 2022 | -1.864M |
| December 31, 2021 | -2.703M |
| September 30, 2021 | -1.759M |
| June 30, 2021 | 6.203M |
| March 31, 2021 | -10.30M |
| December 31, 2020 | -4.856M |
| September 30, 2020 | -3.009M |
| Date | Value |
|---|---|
| June 30, 2020 | 0.859M |
| March 31, 2020 | -5.754M |
| December 31, 2019 | -6.037M |
| September 30, 2019 | 3.063M |
| June 30, 2019 | -9.257M |
| March 31, 2019 | -12.29M |
| December 31, 2018 | -5.183M |
| September 30, 2018 | -15.07M |
| June 30, 2018 | -9.993M |
| March 31, 2018 | -26.22M |
| December 31, 2017 | -10.57M |
| September 30, 2017 | -9.981M |
| June 30, 2017 | -6.517M |
| March 31, 2017 | -16.32M |
| December 31, 2016 | -9.951M |
| September 30, 2016 | -13.41M |
| June 30, 2016 | 8.631M |
| March 31, 2016 | -2.934M |
| December 31, 2015 | -9.203M |
| September 30, 2015 | -9.744M |
| June 30, 2015 | -29.74M |
| March 31, 2015 | -5.974M |
| December 31, 2014 | -11.84M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Innoviva, Inc. | -83.42M |
| Collegium Pharmaceutical, Inc. | -15.05M |
| Johnson & Johnson | 5.534B |
| Ligand Pharmaceuticals, Inc. | 48.51M |
| Harrow, Inc. | -17.27M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 39.66M |
| Total Expenses (Quarterly) | 31.27M |
| EPS Diluted (Quarterly) | 0.1368 |
| Enterprise Value | 471.26M |
| Gross Profit Margin (Quarterly) | 95.36% |
| Profit Margin (Quarterly) | 21.16% |
| Earnings Yield | 7.96% |
| Operating Earnings Yield | 5.65% |
| Normalized Earnings Yield | 9.737 |